Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPARGC1β and CNTN4 Genotype in Aspirin Therapy
NCT02970604Phase 4Unknown
- Sponsor
- Royal College of Surgeons of England
- Start
- May 2016
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in cardiovascular diseases (CVD) (2 arms), sponsored by Royal College of Surgeons of England. Primary endpoint: Urinary Thromboxane B2/Creatinine Ratio. Status: unknown.
02
Drugs
aspirin
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT02970604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970604.